| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort |
| Creator | Taïeb et al. |
| Author | Lina Sayah |
| Author | Kathrin Heinrich |
| Author | Volker Kunzmann |
| Author | Alice Boileve |
| Author | Geert Cirkel |
| Author | Sara Lonardi |
| Author | Benoist Chibaudel |
| Author | Anthony Turpin |
| Author | Tamar Beller |
| Author | Vincent Hautefeuille |
| Author | Caterina Vivaldi |
| Author | Thibault Mazard |
| Author | Lucile Bauguion |
| Author | Monica Niger |
| Author | Gerald W. Prager |
| Author | Clelia Coutzac |
| Author | C. Benedikt Westphalen |
| Author | Edouard Auclin |
| Author | Lorenzo Pilla |
| Abstract | BACKGROUND: Immune checkpoint inhibitors (ICIs) improve oncological outcomes in patients with microsatellite instability-high (MSI) or mismatch repair-deficient (dMMR) advanced solid tumours. Nevertheless, based on limited published data, the outcome of patients with MSI/dMMR pancreatic ductal adenocarcinoma (PDAC) seems poorer when compared to other malignancies. This multi-institutional analysis sought to assess the efficacy and tolerability of ICIs in a large real-world cohort of patients with MSI/dMMR PDAC. METHODS: We retrospectively collected data from patients with MSI/dMMR advanced PDAC treated with ICIs in 16 centers. Progression-free survival and overall survival were calculated from the start of treatment, and we report objective response and disease control rates according to RECIST V1.1. RESULTS: Thirty-one MSI/dMMR advanced PDAC patients were identified. Twenty-five patients received single-agent anti-PD-1 antibodies, three patients received the combination of nivolumab and ipilimumab and three patients received immunotherapy in combination with chemotherapy. Among 31 evaluable patients, 15 (48.4%) had an objective response (three complete responses and 12 partial responses), and six (19.4%) had stable disease. With a median follow-up of 18 months, the median progression-free survival (PFS) was 26.7 months and the median overall survival (OS) was not reached. Disease control rates (DCRs) among patients with only one line of prior therapy (N = 17) was 76.5%. Grade 3-4 treatment-related adverse events were not observed. CONCLUSION: This retrospective analysis suggests that ICIs are effective and well tolerated in patients with MSI/dMMR advanced PDAC. Hence, our work supports the use of PD-1 inhibition in this group of patients with high unmet medical need. |
| Publication | European Journal of Cancer (Oxford, England: 1990) |
| Volume | 188 |
| Pages | 90-97 |
| Date | 2023-04-23 |
| Journal Abbr | Eur J Cancer |
| Language | eng |
| DOI | 10.1016/j.ejca.2023.04.012 |
| ISSN | 1879-0852 |
| Short Title | Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma |
| Library Catalog | PubMed |
| Extra | PMID: 37229836 |
| Tags | Adenocarcinoma, Antineoplastic Agents, Immunological, Humans, Immune checkpoint inhibitors, Microsatellite Instability, Microsatellite Repeats, MSI/dMMR, Pancreatic adenocarcinoma, Pancreatic Neoplasms, Retrospective Studies |
| Date Added | 2023/06/08 - 14:49:28 |
| Date Modified | 2024/10/10 - 16:25:47 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
